Last Price
28.80
Today's Change
+0.105 (0.36%)
Day's Change
28.00 - 29.12
Trading Volume
194,511
Exchange: NASDAQ Global Select NASDAQ Global Select
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. John M. Evans M.B.A. Mr. John M. Evans M.B.A.
Full Time Employees: 472 472
IPO Date: 2020-02-06 2020-02-06
CIK: 0001745999 0001745999
ISIN: US07373V1052 US07373V1052
CUSIP: 07373V105 07373V105
Beta: 1.86 1.86
Last Dividend: 0.00 0.00
Dcf Diff: 38.90 38.90
Dcf: -0.48 -0.48
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.